News coverage about Qiagen (NASDAQ:QGEN) has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 6,000 blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Qiagen earned a coverage optimism score of 1.50 on their scale. InfoTrie also gave media stories about the company an news buzz score of 7 out of 10, meaning that recent news coverage is likely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Qiagen’s score:
- Qiagen Breaks Above 200-Day Moving Average – Bullish for QGEN (nasdaq.com)
- QIAGEN’s New Offerings to Broaden Hematology Testing Suite (zacks.com)
- QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System (finance.yahoo.com)
- Qiagen (QGEN) Receiving Favorable News Coverage, Report Finds (americanbankingnews.com)
- Qiagen NV (QGEN) Expected to Post Quarterly Sales of $409.01 Million (americanbankingnews.com)
A number of brokerages have recently commented on QGEN. BidaskClub upgraded Qiagen from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Morgan Stanley boosted their price target on Qiagen from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 31st. Barclays reissued a “buy” rating on shares of Qiagen in a research report on Tuesday, October 30th. Zacks Investment Research reaffirmed a “hold” rating on shares of Qiagen in a research report on Wednesday, November 14th. Finally, Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday, October 30th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $39.13.
Qiagen (NASDAQ:QGEN) last announced its quarterly earnings results on Monday, October 29th. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.02. The firm had revenue of $377.90 million during the quarter, compared to the consensus estimate of $380.11 million. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Further Reading: Why do companies issue stock splits?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.